Inventor · disambiguated record
Rong Wang
Also filed as: WANG RONG · WANG RONG-FU
25 granted patents·17 pending applications·760 citations·filing 1993–2024
97Inventor score
Top patents by PatentIndex Score
42 records- 0197US5840839AAlternative open reading frame DNA of a normal gene and a novel human cancer antigen encoded thereinUS HEALTH·Filed 1996·Granted Nov 24, 1998·242 cites·20 claims
- 0295US7632499B2Anti-myostatin antibodiesLILLY CO ELI·Filed 2006·Granted Dec 15, 2009·64 cites·10 claims
- 0393US5792664AMethods for producing and analyzing biopolymer laddersUNIV ROCKEFELLER·Filed 1995·Granted Aug 11, 1998·99 cites·51 claims
- 0491US7635760B2Anti-myostatin antibodiesLILLY CO ELI·Filed 2006·Granted Dec 22, 2009·35 cites·3 claims
- 0591US7619057B2MHC class II restricted T cell epitopes from the cancer antigen, NY ESO-1US HEALTH·Filed 2001·Granted Nov 17, 2009·25 cites·12 claims
- 0689US8754046B2MHC class II restricted T cell epitopes from the cancer anitgen, NY ESO-1WANG RONG-FU·Filed 2009·Granted Jun 17, 2014·12 cites·23 claims
- 0789US7745583B2Anti-myostatin antibodiesLILLY CO ELI·Filed 2009·Granted Jun 29, 2010·19 cites·6 claims
- 0888US5831016AIdentification of TRP-2 as a human tumor antigen recognized by cytotoxic T lymphocytesUS HEALTH·Filed 1996·Granted Nov 3, 1998·74 cites·14 claims
- 0987US6750061B2Method and product for the sequence determination of peptides using a mass spectrometerUNIV ROCKEFELLER·Filed 2001·Granted Jun 15, 2004·26 cites·12 claims
- 1087US6132980AAntibodies specific for TRP-2 a human tumor antigen recognized by cytotoxic T lymphocytesUS HEALTH·Filed 1998·Granted Oct 17, 2000·38 cites·11 claims
- 1186US8066995B2Anti-myostatin antibodiesDAVIES JULIAN·Filed 2009·Granted Nov 29, 2011·11 cites·18 claims
- 1284US8211445B2PSM peptides as vaccine targets against methicillin-resistant StaphylococcusOTTO MICHAEL·Filed 2009·Granted Jul 3, 2012·3 cites·16 claims
- 1382US6800613B2Prophylactic and therapeutic treatment of infectious and other diseases with mono- and disaccharide-based compoundsCORIXA CORP·Filed 2001·Granted Oct 5, 2004·22 cites·53 claims
- 1480US7902159B2Prophylactic and therapeutic treatment of infectious and other diseases with mono- and disaccharide-based compoundsCORIXA CORP·Filed 2007·Granted Mar 8, 2011·5 cites·53 claims
- 1580US6271037B1Method and product for the sequence determination of peptides using a mass spectrometerUNIV ROCKEFELLER·Filed 1993·Granted Aug 7, 2001·29 cites·45 claims
- 1675US8318697B2Prophylactic and therapeutic treatment of infectious and other diseases with mono- and disaccharide-based compoundsPERSING DAVID H·Filed 2011·Granted Nov 27, 2012·3 cites·13 claims
- 1772US9447144B2MHC class II restricted T cell epitopes from the cancer antigen, NY ESO-1US HEALTH·Filed 2014·Granted Sep 20, 2016·0 cites·15 claims
- 1871US2025066794A1Application of PRDX5 and GPX4 Genes in Preparation of Drugs for Castration-resistant Prostate CancerUNIV JIANGNAN·Filed 2024·Application pending·0 cites
- 1970US7001600B1Identification of TRP-2 as a human tumor antigen recognized by cytotoxic T lymphocytesUS HEALTH·Filed 2000·Granted Feb 21, 2006·1 cites·74 claims
- 2069US7084239B1Cancer peptides of NY-ESO-1/CAG-3US HEALTH·Filed 1998·Granted Aug 1, 2006·18 cites·41 claims
- 2167US2005153454A1Method for detecting post-translational modification of peptidesSCRIPPS RESEARCH INST·Filed 2004·Application pending·0 cites
- 2264US2025019777A1Isolation, purification, in vitro cultivation, and identification of symbiodinium species symbiotic with soft coralUNIV HAINAN NORMAL·Filed 2024·Application pending·0 cites
- 2361US6087110AAlternative open reading frame DNA of a normal gene and a novel human cancer antigen encoded thereinUS HEALTH·Filed 1998·Granted Jul 11, 2000·15 cites·20 claims
- 2460US10251912B2MHC class II restricted T cell epitopes from the cancer antigen, NY ESO-1US HEALTH·Filed 2016·Granted Apr 9, 2019·0 cites·20 claims
- 2560US6083703AIdentification of TRP-2 as a human tumor antigen recognized by cytotoxic T lymphocytesUS HEALTH·Filed 1998·Granted Jul 4, 2000·19 cites·27 claims
- 2658US2023284906A1Risk stratification method for the detection of cancers in precancerous tissuesUNIV MISSOURI·Filed 2023·Application pending·0 cites
- 2758US2022339175A1Application of Stachyose in Preparation of Drug for Treating Castration-Resistant Prostate CancerUNIV JIANGNAN·Filed 2022·Application pending·0 cites
- 2857US2025032554A1Medicine for Preventing or Treating Enteritis and Intestinal CancerANHUI HYGEIANCELLS BIOMEDICAL CO LTD·Filed 2022·Application pending·0 cites
- 2955US2003105032A1Phophylactic and therapeutic treatment of infectious and other diseases with mono-and disaccharide-based compoundsFiled 2002·Application pending·0 cites
- 3054US7015312B1Antibodies to the protein product encoded by ORF3 of the TRP-1 gene and compositions and kits thereofUS HEALTH·Filed 2000·Granted Mar 21, 2006·0 cites·15 claims
- 3154US2004147480A1Prophylactic and therapeutic treatment of infectious and other diseases with mono-and disaccharide-based compoundsCORIXA CORP·Filed 2004·Application pending·0 cites
- 3253US11707724B2Preparation method of bacterial cellulose-defective molybdenum disulfide heterojunction material for treating radioactive wastewaterUNIV SW SCI & TECH SWUST·Filed 2021·Granted Jul 25, 2023·0 cites·7 claims
- 3353US2004023314A1Mutant fibronectin and tumor metastasisBAYLOR COLLEGE MEDICINE·Filed 2003·Application pending·0 cites
- 3452US2024091233A1Use of wee1 kinase inhibitors in the treatment of cancerIMPACT THERAPEUTICS SHANGHAI INC·Filed 2022·Application pending·0 cites
- 3551US2022347322A1Method of treating arteriovenous malformations by targeting the ephrin pathwayUNIV CALIFORNIA·Filed 2020·Application pending·0 cites
- 3649US2003077289A1Use of cell-penetrating peptides to generate antitumor immunityFiled 2002·Application pending·0 cites
- 3747US2023116387A1HIGH-PURITY PURIFICATION TECHNIQUE FOR Gc PROTEINKK MEDICALBIARA·Filed 2021·Application pending·0 cites
- 3847US2003139356A1Prophylactic and therapeutic treatment of infectious and other diseases with mono- and disaccharide-based compoundsFiled 2001·Application pending·0 cites
- 3946US2011229560A1Nlrc5 as a target for immune therapyWANG RONG-FU·Filed 2009·Application pending·0 cites
- 4042US7341874B2Method for detecting post-translation modifications of peptidesUNIV ROCKEFELLER·Filed 2004·Granted Mar 11, 2008·0 cites·7 claims
- 4139US2009209620A1Direct Reversal Of The Suppressive Function Of CD4+Regulatory T Cells Via Toll-Like Receptor 8 SignalingWANG RONG-FU·Filed 2006·Application pending·0 cites
- 4235US2008026986A1Reversal of the suppressive function of specific t cells via toll-like receptor 8 signalingWANG RONG-FU·Filed 2007·Application pending·0 cites
Join the waitlist — get patent alerts
Get an alert when Rong Wang files or is granted a new patent.
We store only your email — no account needed. See our privacy policy.
Identity basis: PatentsView inventor disambiguation (2025Q4-odp release). How scoring works →